Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.56 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.56 |
| ▸ | ABAT | P80404 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16229624 | 0.86 | PTGS2 (0.57) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL358930 | 0.86 | CA12 (0.62) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL13926061 | 0.86 | PTGS2 (0.84) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL11469172 | 0.85 | ALDH1A1 (0.58) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL5033639 | 0.85 | ALDH1A1 (0.58) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL685901 | 0.84 | PTGS2 (0.67) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL28677845 | 0.83 | ERN1 (0.56) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL2608366 | 0.83 | PTGS2 (0.65) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL30362132 | 0.82 | ALDH1A1 (0.61) | PTGS2ALDH1A1HPGDTRIM24ALDH5A1 | |
| SCHEMBL18373091 | 0.82 | ALDH1A1 (0.55) | PTGS2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119662027-A | Preparation method and application of skidproof flexible silica gel with skin-friendly matte surface | 东莞市莎利特新材料科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-107501392-B | 1-substituted-beta-carboline-3-formyl-Trp-Trp-Thr-OBzl, and synthesis and application thereof | 首都医科大学 | 2021-06-08 | — | — | CN | claimed |
| CN-106349148-B | New indole class compound with anti-tumor metastasis and anti-inflammatory activity, synthesis and application | 首都医科大学 | 2019-07-05 | — | — | CN | claimed |
| US-10191398-B2 | Electrophotographic photoconductor, image forming apparatus, and process cartridge | RICOH COMPANY, LTD. (JP) | 2019-01-29 | — | — | US | claimed |
| CN-106349148-A | Novel indoles compound having anti-tumor metastasis activity and anti-inflammatory activity, as well as synthesis and application of novel indoles compound | 首都医科大学 | 2017-01-25 | — | — | CN | claimed |
| CN-105315338-A | LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2016-02-10 | — | — | CN | claimed |
| CN-105273055-A | RGD tetrapeptide-modified beta-carboline, preparation, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-27 | — | — | CN | claimed |
| CN-105273054-A | YIGSR-modified beta-carboline, preparation, nano-structure, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-27 | — | — | CN | claimed |
| CN-105273047-A | Amino-acid benzyl ester modified beta-carboline, activity, nanometer structure, synthesis and application | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-27 | — | — | CN | claimed |
| CN-105237618-A | Amino acid benzyl ester-modified beta-carbolines, synthesis, nanostructures, activities, and applications | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-13 | — | — | CN | claimed |
| CN-105218636-A | The β-carboline that LPNISKP modifies, its preparation, nanostructure, active and application | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-06 | — | — | CN | claimed |
| CN-105218628-A | The β-carboline that tryptophan benzyl ester is modified, its synthesis, nanostructure, active and application | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-06 | — | — | CN | claimed |
| CN-105153277-A | Beta-carboline modified by KE as well as preparation, nanostructure, activity and application of the same | UNIV CAPITAL MEDICAL SCIENCES | 2015-12-16 | — | — | CN | claimed |
| CN-104211699-A | Beta-carboline derivatives, preparation, nano structure, antitumor activity and applications thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-12-17 | — | — | CN | claimed |
| EP-1879661-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-01-23 | — | — | EP | claimed |
| WO-2006119821-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLCHAFT AUF AKTIEN (DE) | 2006-11-16 | — | — | WO | claimed |
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4642471-A1 | PLANT HYDROETHANOLIC EXTRACTS AND USES THEREOF | IMMUNE & GENETICS PROTOCOLS LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577227-B2 | WDR5 inhibitors and modulators | WDR1, WDR5, WDR3 | PTGS2 3588/4885CA12 4481/4885CA1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.